Reshoring EO aims to streamline permitting, approval, and oversight of US drug manufacturing
By EsqSocial Corporation 08/05/25
On May 5, 2025, President Donald Trump signed an Executive Order (EO) aiming to promote American-made prescription drugs (“Reshoring Manufacturing EO”). The EO directs federal agencies to eliminate regulatory hurdles, accelerate permitting, and prioritize domestic facilities to restore the United States’ capacity to manufacture prescription drugs and critical inputs such as active pharmaceutical ingredients (APIs). The primary goals of the executive order are to reduce U.S. reliance on foreign...
By: Hogan Lovells